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Aim: Personality disorder is a common co-occurrence (‘comorbidity’) among patients with bipolar 
disorder and appears to affect outcome negatively. However, there is little knowledge about the 
impact of this comorbidity in the early phases of bipolar disorder. We examined the prevalence 
and effect of personality disorder co-occurrence on outcome in a cohort of youth with first 
episode mania with psychotic features.  
Methods: Seventy-one first episode mania patients, aged 15 to 29, were assessed at baseline, 6, 
12, and 18 months as part of a randomized controlled trial of olanzapine and chlorpromazine as 
add-on to lithium in first episode mania with psychotic features. The current study involved 
secondary analysis of trial data.   
Results: A co-occurring clinical personality disorder diagnosis was present in 16.9% of patients. 
Antisocial and narcissistic personality disorder were the most common diagnoses. Patients with 
co-occurring personality disorder had higher rates of readmission to hospital, lower rates of 
symptomatic recovery and poorer functional levels at 6 months, but these differences 
disappeared after 12 and 18 months.  
Conclusions: In the early phase of bipolar disorder, patients with personality disorder comorbidity 
display delayed symptomatic and functional recovery and increased likelihood to need hospital 
readmissions. These observations suggest that routine assessment for personality disorder and 
specific interventions are important in order to improve short-term treatment efficacy in this 
subgroup.  
 





Personality disorder (PD) commonly co-occurs among people with bipolar disorder (BD), with an 
estimated prevalence between 20% and 80% (Carpenter, Clarkin, Glick, & Wilner, 1995; 
Zimmerman, Balling, Chelminski, & Dalrymple, 2020; Zimmerman & Morgan, 2013). A recent 
systematic review (Bezerra-Filho et al., 2015) identified that 41.2% of euthymic BD patients had 
at least one co-occurring (‘comorbid’) PD. This wide variability in reported prevalence of PD 
among individuals with BD might be influenced by differences in the method of assessment, the 
measures used, and potential effects of mental state features upon the assessment of personality 
pathology (George, Miklowitz, Richards, Simoneau, & Taylor, 2003). Diagnosis of PD might also be 
difficult in people with BD because of ambiguity or similarities among diagnostic criteria for BD 
and PD (Blacker & Tsuang, 1992; Ghaemi & Barroilhet, 2015; Zimmerman & Morgan, 2013). 
Nonetheless, these data suggest that the prevalence of PD among people with BD is considerably 
higher than among the general population, which is estimated to be 9.6% in high-income 
countries (Quirk, Berk, et al., 2016; Winsper et al., 2020). 
 
Few studies have focused upon PD co-occurrence in the early phase of BD (Yen et al., 2015). A key 
challenge in studying this phase of disorder is that both personality and mood-related 
psychopathology become clinically apparent from puberty through to young adulthood, 
frequently co-occur, can reinforce one another (presence of one disorder leading to the 
amplification of the manifestations of the other), and can be difficult to differentiate clinically due 
to some similarities in symptomatology such as irritability, impulsivity and mood instability for 
example (Chanen, Berk, & Thompson, 2016). Kutcher, Marton, and Korenblum (1990) assessed 
20 euthymic bipolar teens and found that 35% met DSM-III-R criteria for at least one PD. The 
group with BD and PD differed significantly from the BD without PD group in terms of increased 
 
 
lithium unresponsiveness and neuroleptic treatment at time of personality assessment, but not 
in terms of age, sex, age of illness onset, serum lithium level, rapid cycling, substance abuse history, 
alcohol abuse history, or number of suicide attempts. 
 
Some data are available for older samples with first episode mania (FEM). Dunayevich et al. (1996) 
compared rates of comorbid PD among adult in-patients with FEM (mean age 27 years) and 
individuals who had experienced multiple episodes of mania (mean age 43 years). They found 
that the prevalence of PD in the first-episode group (33%) was half that of the multi-episode group 
(65%). Pica et al. (1990), examined rates of PD among 26 inpatients with recent-onset BD and 
schizoaffective disorder (bipolar type). Using a structured interview after affective symptoms had 
stabilized, they observed that 62% of their sample were diagnosed with comorbid PD, mostly 
belonging to DSM-III Cluster B.  
 
PD can have adverse effects upon treatment outcomes for a wide range of mental state (formerly 
Axis I) disorders (Hasin et al., 2011; Skodol et al., 2011). For BD, the presence of a concurrent PD 
has been associated with an increased likelihood of hospitalization, longer time to symptom 
stabilization, more chronic impairments in social and occupational functioning, greater medical 
comorbidity, increased levels of suicidality, and greater utilization of psychiatric services (Bieling 
et al., 2003; Quirk et al., 2017; Quirk, Stuart, et al., 2016; Zimmerman et al., 2020). Co-occurring 
PD has also been found to be a significant predictor of mood episode severity (Post et al., 2018), 
medication non-adherence (Colom et al., 2000), and higher risk of relapse (Gasperini, Scherillo, 
Manfredonia, Franchini, & Smeraldi, 1993), although a study reported no effect on functional 




Data on the effects of co-occurring PD in the early phase of BD are scarce. In a recent publication, 
Ng et al. (2017) reported that amongst individuals with BD, both the presence and the severity of 
PD symptoms (mainly cluster B and C) are correlated with the rate of onset of a manic/mixed 
episode and of conversion from less severe BD to bipolar I disorder. Dunayevich et al. (2000) 
reported that while all FEM patients had similar symptomatic and functional outcome 12 months 
following discharge from hospital, those with co-occurring PD had poorer syndromal recovery (8 
contiguous weeks without a depressive, mixed, or manic syndrome). 
 
In summary, little is known about the prevalence of PD co-occurrence among younger patients, 
who are closer to the usual average age of onset of a FEM. Also, the little data available suggest 
that PD might have a negative influence upon patients’ outcomes in early phase of BD. There is a 
need to clarify the effect that co-ocurring PD might have on the outcomes of clinical trials 
(Kavanagh, Brennan-Olsen, et al., 2019). Indeed, while the early phase of non-affective psychoses 
has received extensive attention, research focusing on the early phase of affective psychoses is 
much more limited (Conus & McGorry, 2002), despites their public health significance (Conus, 
Macneil, & McGorry, 2014); the identification of factors that may influence outcomes is therefore 
important (Conus et al., 2010).  
In this context, the current study had two aims: (i) to report the prevalence of co-occurring PD in 
adolescents and young adults who present with a first episode of psychotic mania; and (ii) to 
examine the effects that co-ocurring PD has on short-term treatment outcomes. We hypothesized 
that individuals with co-occurring PD would have poorer outcomes across the treatment period, 





Participants and Setting 
The study includes 71 participants (68% males), aged between 15-29 years, who attended the 
Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne, Australia(October 
2001-February 2006). At entry, these patients met DSM-IV criteria (American Psychiatric 
Association, 1994) for a FEM with psychotic features and had a minimum baseline score of 20 on 
the Young Mania Rating Scale (YMRS; Young, Biggs, Ziegler, & Meyer, 1978). All participants 
received a diagnosis of either BD I or schizoaffective disorder at 12- and 18-month follow-up.  
 
All participants were drawn from a larger randomised controlled trial (RCT), which compared 
olanzapine versus chlorpromazine as an adjunct to lithium for the treatment of a first manic or 
mixed episode with psychotic features (Conus et al., 2015). The study was approved by the 
Melbourne Health Research and Ethics Committee and participants provided written informed 
consent.  
 
Participants were prospectively evaluated using diagnostic, symptomatic, and functional 
assessments over 18 months by research assistants. They received 18 months of treatment, 
provided by both a clinical psychologist and a psychiatrist, which included assertive case 




Exclusion criteria were as follows: (i) immediate risk of harm to self or others at commencement 
of the RCT; (ii) use of neuroleptic medication or mood-stabilisers in the two months preceding 
admission to EPPIC; (iii) presence of organic mental disease, including intellectual disability: (iv) 
having a history of clinically significant medical illness (liver or renal insufficiency, significant 
cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological or metabolic 
disturbances), clinically relevant biochemical or haematological abnormalities; (v) being pregnant 
or lactating; (vi) having a history of epilepsy, a severe drug allergy or hypersensitivity; and/or (vii) 
having insufficient fluency in English.   
 
Measures 
The Structured Clinical Interview for DSM-IV Axis I disorders-patient version (SCID-I/P; First, 
Spitzer, Gibbon, & Williams, 2007) was completed at 8 weeks, 12 and 18 months to ensure 
stability of diagnosis. PD diagnoses were based on a consensus process involving two senior 
psychologists (MH & CM), a senior psychiatrist (LK) and the clinical case manager involved in 
patient’s treatment. Diagnoses were made using DSM-IV diagnostic criteria, and were derived 
from data obtained through longitudinal follow up by each participant’s treating team and from 
information provided by family. A conservative approach was taken, whereby diagnosis of PD was 
made only if the patient met full criteria, outside of significant episodes of mood disturbance. 
Individuals who presented with sub-syndromal PD were not included in the PD group. The 




The outcomes of interest included remission of mood symptoms, occupational functioning, 
relapse, and medication adherence. These variables were dichotomised for analysis (e.g., 
remission of manic symptoms achieved/not achieved). The YMRS and the Hamilton Depression 
Rating Scale (HAMD-21; Hamilton, 1967) were used as measures of remission from mood 
symptoms. In line with usual cut-offs, YMRS score of <12, and a HAMD-21 score of <8 were 
considered as remission from manic and depressive syndrome respectively. The outcomes were 
assessed by Research Assistants who were not aware of the PD diagnostic status. The Brief 
Psychiatric Rating Scale was used to assess symptoms, either as a global score or as psychotic 
symptom scores on the sub-scales (BPRS; Overall et al., 1962). 
 
Vocational/education status was assessed using the Modified Vocational Status Index (Tohen et 
al., 2000). Occupational functioning was defined as engagement in either full or part time (>30 
hours/week) work or studies. We assessed functioning with the Global Assessment of Functioning 
(GAF; American Psychiatric Association, 1994), and Social and Occupational Functioning Scale 
(SOFAS; American Psychiatric Association, 1994). Relapse was identified when there was 
intervention (including increase in medication, hospital admission, emergency visit, acute services 
involvement) for a mood or psychotic episode. Total number of mood episodes included the index 
episode plus any relapses and switches to a different mood episode.  
 
Data Analysis 
Descriptive statistics including means, standard deviations (SDs), frequencies, and percentages 
are presented for each PD to depict the characteristics of the patients. To assess the relationship 
 
 
between the presence of comorbid PD and outcomes following a FEM, a series of logistic 
regression analyses were conducted with PD (present/absent) as the dependent variable, and the 
individual demographic and outcome variables as independent variables.  From these analyses, 
odds ratios (OR) and the 95% confidence intervals (CI) of the ORs were derived. The Wald statistic 
(z) was used to determine significance of associations.  Last observation carried forward was used 
for missing data at follow-up time points.  
 
RESULTS 
Prevalence of comorbid personality disorders 
Data were available for 71 participants. Figure 1 shows the demographic characteristics of the 
two groups and the frequency for each PD. Twelve (16.9%) of the participants were diagnosed 
with a PD (8 males (16.7% of the males) and 4 females (17.4% of the females)), with two of these 
participants meeting criteria for two PDs (both males, with antisocial and narcissistic PD). The 






Demographic and baseline characteristics 
Demographic and baseline characteristics of patients with and without co-occurring PD are 
reported in Table 1. Bivariate logistic regression analyses indicated that there were no significant 
group differences in age, gender, education, unemployment, baseline symptoms or functioning, 
substance use disorder (SUD) at baseline, or history of trauma or suicide attempts. Symptom 
intensity (BPRS scores) was similar in both sub-groups at baseline regarding global 







Table 1. Demographic and baseline characteristics of those with BD with and without comorbid 
PD. 
  Comorbid PD     
  Yes No  95% CI  
 Statistic (n=12) (n=59) OR Lower Upper p-value 
Age (years) M(SD) 21.2(2.2) 21.5(3.0) 0.96 0.77 1.20 .710 
Gender %Female %(n) 33.3(4) 32.2(19) 1.05 0.28 3.94 .939 
Years in school %(n) 11.7(1.5) 11.7(1.5) 0.99 0.65 1.49 .942 
Unemployed %(n) 18.2(2) 40.7(24) 0.32 0.06 1.63 .172 
YMRS M(SD) 35.8(7.4) 35.7(7.4) 1.00 0.92 1.09 .993 
HAMD-21 M(SD) 7.4(5.2) 8.4(6.6) 0.97 0.88 1.08 .625 
GAF M(SD) 30.6(9.8) 31.5(11.1) 0.99 0.93 1.05 .778 
SOFAS M(SD) 34.4(13.7) 35.5(11.7) 0.99 0.94 1.04 .782 
SUD %(n) 40.0(4) 45.2(14) 0.81 0.19 3.45 .775 
Hx of trauma %(n) 72.7(8) 67.9(36) 1.26 0.30 5.35 .755 
Hx of SA %(n) 27.3(3) 10.7(6) 3.13 0.65 15.08 .156 
CI, confidence interval; *p<0.05;**p<0.01; OR, odds ratio; YMRS, Young Mania Rating Scale; HAMD-21, 
Hamilton Depression Rating Scale; GAF, Global Assessment of Functioning Scale; SOFAS, Social and 
Occupational Functioning Scale; SUD, substance use disorder; Hx, history; SA, suicide attempt. 
 
Outcomes 
Comparison of outcomes, over the 18-month follow-up between patients with and without co-
occurring PD, are reported in Table 2.   
 
At 6-month follow-up, patients with co-occurring PD were less likely to have reached remission of 
manic (z=7.81, p=.005) and depressive (z=5.06, p=.024) symptoms. In addition, these patients had 
significantly poorer functional levels at 6 months based on the SOFAS (z=4.86, p=.027) and GAF 
(z=6.87, p=.009). These differences however were not apparent at 12 and 18 months. Finally, 
these patients had more inpatient admissions overall than those who did not have a co-occurring 






Table 2. 6, 12, and 18 month outcomes of those with BD with and without comorbid PD 
  Comorbid PD     
  Yes No  95% CI  
Variable of interest Statistic (n=12) (n=59) OR Lower Upper p-value 
Remission on YMRS        
6 months** %(n) 54.5(6) 91.1(51) 0.12 0.03 0.53 .005 
12 months %(n) 88.9(8) 72.7(40) 3.00 0.35 26.06 .319 
18 months1 %(n) 100.0(10) 77.4(41)     
Remission on HAMD-21        
6 months* %(n) 36.4(4) 73.2(41) 0.21 0.05 0.82 .024 
12 months %(n) 55.6(5) 75.9(41) 0.40 0.09 1.70 .213 
18 months %(n) 87.5(7) 76.5(39) 2.15 0.24 19.3 .493 
GAF        
6 months** M(SD) 51.5(16.2) 64.3(12.0) 0.93 0.89 0.98 .009 
12 months M(SD) 55.7(15.1) 61.8(16.6) 0.98 0.94 1.02 .265 
18 months M(SD) 58.9(13.8) 63.4(16.3) 0.98 0.94 1.02 .416 
SOFAS        
6 months* M(SD) 55.2(17.3) 65.4(11.6) 0.94 0.89 0.99 .027 
12 months M(SD) 55.6(13.7) 62.4(16.6) 0.98 0.94 1.01 .208 
18 months M(SD) 57.4(13.6) 63.7(17.0) 0.98 0.94 1.02 .272 
Employed/studying≥30 
hours/week 
       
6 months %(n) 18.2(2) 50.0(27) 0.22 0.04 1.13 .069 
12 months %(n) 54.5(6) 60.7(34) 0.78 0.22 2.86 .703 
18 months %(n) 50.0(5) 65.5(36) 0.52 0.14 2.05 .357 
Clinical outcomes        
≥1 relapse %(n) 41.7(5) 56.4(31) 0.55 0.16 1.96 .359 
Number of mood 
episodes 
M(SD) 2.2(0.9) 2.0(1.0) 1.17 0.62 2.2 .631 
Inpatient 
admissions** 
M(SD) 3.0(2.2) 1.5(1.1) 1.86 1.20 2.90 .006 
CI, confidence interval; *p<0.05;**p<0.01; OR, odds ratio; YMRS, Young Mania Rating Scale; HAMD-21, 
Hamilton Depression Rating Scale; GAF, Global Assessment of Functioning Scale; SOFAS, Social and 
Occupational Functioning Scale. 




To our knowledge, this is the first study to examine both the prevalence and outcomes for the 
range of co-occurring PD in first episode psychotic mania. The prevalence rate for PD observed in 
our cohort is almost twice that reported for general community but is substantially lower than 
rates reported in multi-episode cohorts. It is also noteworthy that, although Cluster B PD  was the 
most frequent (including mainly antisocial and narcissistic PD, fewer borderline PD and no 
 
 
histrionic PD), the rate of borderline PD in the current study (2.8%) was consistent with general 
population rates (Leichsenring, Leibing, Kruse, New, & Leweke, 2011), and is considerably lower 
than among other bipolar I samples, reporting rates of up to 40% (Preston, Marchant, Reimherr, 
Strong, & Hedges, 2004); this low prevalence could be explain in various ways. First, several 
authors have suggested that lower rates of co-occurring PD in the early phase of BD might indicate 
that the phenotype of PD develops over time as a consequence of BD. Chanen et al. (2016) have 
also noted that borderline and mood-related psychopathology can reinforce one another, and 
other authors have suggested that recurrent episodes or chronic state might induce the 
progressive development, or at least exacerbation, of pathological personality traits (Carpenter 
et al., 1995; Dunayevich et al., 1996). Second, individuals without PD might be more likely be 
accepted for treatment in primary care, where prevalence rates for PD are lower than in specialist 
mental health settings (Moran, Jenkins, Tylee, Blizard, & Mann, 2000), rather than at specialist 
treatment centres where previous studies have been conducted. Finally, it is possible that the 
higher relapse rates and more chronic course of illness among patients with PD would 
progressively lead to ‘enrichment’ of bipolar samples in specialist settings with patients displaying 
such comorbidity. This illustrates “Berkson’s bias” (Berkson, 1946), whereby people who meet 
criteria for multiple disorders, compared to those with just one disorder, are more likely to be 
treatment seeking, and is likely to lead to inflated levels of co-occurrence. 
 
The prevalence of co-occurring PD in this study is however lower than that reported in previous 
FEM studies (Dunayevich et al., 1996; Pica et al., 1990).This might be explained by the lower 
average age of the patients involved in our study, or by methodological and clinical setting 
differences. Specifically, both Dunayevich et al. (1996) and Pica et al. (1990) were based on 
assessment during acute episode. In contrast, our PD diagnostic procedure is based on a 18-
 
 
month longitudinal assessment, including information gathered not only with patients but also 
with numerous other sources (relatives), allowing a possibly more accurate distinction between 
‘state’ and ‘trait’ features. Our method was consistent with that recommended by Bajaj and Tyrer 
(2005) who suggested that due to the potential confounding effect of state versus trait 
characteristics during acute bipolar episodes, the confirmation of PD diagnosis in BD patients 
should only occur during the euthymic phase. As such, the prevalence of PD comorbidity in the 
present study might be closer to what is likely to be found in centres treating youth. 
 
Consistent with previous studies, co-occurring PD was associated with poorer outcomes early in 
the course of treatment, such as lower rates of remission of mood symptoms at 6 months. 
However, by 12 and 18 months there were no significant differences between groups. Reliable 
data on adherence to treatment were not available for most patients and therefore, we could not 
explore its influence upon outcome. Indeed, available data suggested that patients with PD are 
less likely to adhere to treatment, which should be explored in future studies. The observation of 
a higher rate of hospital admission is consistent with poorer clinical outcome, higher severity of 
mood episodes (Post et al., 2018), and might also be linked to differences in behaviour during 
relapses, mainly regarding risk of harm to self or others, which are common factors leading to 
inpatient admission. Lack of statistical power prevented stratifying analyses to explore if the type 
of PD had a differential impact on outcome. 
 
Patients with co-occurring PD had a significantly poorer level of functioning at 6 months. 
Functional recovery after a FEM is generally poor and might lag behind symptom recovery (Conus 
et al., 2006; Strakowski et al., 1998). While targeted intervention addressing functional recovery 
 
 
is an important aspect of treatment following a FEM (Macneil, Hasty, Conus, Berk, & Scott, 2010), 
this finding suggests it might be particularly important when PD co-occurs.  
 
Despite some significant differences in the early phase of recovery, the current findings, 
consistent with Dunayevich et al. (1996), showed no difference between groups on any of the 
symptom or functioning measures at 12 and 18 months. Similarly, no differences were observed 
in the number of mood episodes or relapses rates between groups. It is possible that these 
encouraging findings might be attributed to the specialized comprehensive and early psychosocial 
intervention. Indeed, early intervention for youth with borderline PD, and for young people with 
BD, has been found to result in significant improvement across a broad range of outcomes 
(Chanen, Sharp, & Hoffman, 2017; Chanen & McCutcheon, 2013; Macneil et al., 2012). It might 
also be explained by a ceiling effect, BD patients without PD reaching recovery earlier but then 
failing to improve more, while BD patients with PD reach this level more progressively but finally 
close the gap and then stagnating as well.  
 
There are various limitations to this study. First, the sample size was small and lacked statistical 
power to examine individual PDs and clinical phenomena of low effect size. Second, diagnosis of 
PD was not based on a structured diagnostic tool, such as the Structured Clinical Interview for 
DSM-IV Axis II Disorders (First et al., 2007). However, our longitudinal and expert consensus 
diagnostic approach enabled us to incorporate numerous sources of information (family/patient 
reports, clinical observation/interaction) across 18 months, which were used in addition to 
specific clinical assessment regarding DSM-IV PD criteria. Westen (1997), who questioned the 
utility of direct questions in the assessment of PDs, suggested that the validity of PD diagnosis is 
 
 
likely to be enhanced if observations and direct questions are combined. Third, this study is 
focused on patients with psychotic mania and therefore provides information only for this 
subgroup and might not be relevant to patients who present a FEM without psychotic features or 
with index depression. Finally, our study suggests a need for early, targeted interventions for BD 
patients with comorbid PD. Indeed, prolonged illness might have consequences, such as increased 
risk taking behaviour or exposure to negative life events and higher negative impact on caregivers 
and relatives (Berk et al., 2013; Perlick et al., 2016). However, such factors were not measured in 
the present study, and thus will need to be clarified in future research in order to develop specific 
interventions. 
 
In conclusion, the prevalence of PD co-occurrence among young first-episode psychotic mania 
patients is greater than the population prevalence for PD. The co-occurrence of PD and BD led to 
delayed recovery and higher rates of hospital admissions over the treatment period, but did not 
lead to poorer 12- and 18-month outcomes, in the context of a specialized youth mental health 
service. This suggests a need for early, targeted interventions for this sub-group. Future research 
are required to explore the impact of such specific early interventions.  
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